Previous Page  10 / 12 Next Page
Information
Show Menu
Previous Page 10 / 12 Next Page
Page Background

allied

academies

Page 44

Notes:

Journal of Neurology and Neurorehabilitation Research | Volume 4

November 04-05, 2019 | Melbourne, Australia

Neurology and Neurological Disorders

19

th

International Conference on

J Neurol Neurorehabil Res, Volume 4

A case report of Myasthenia Gravis treated with Plasmapharesis

Theresia Christin

Sriwijaya University, Indonesia

Background:

Myasthenia gravis is a neuromuscular

autoimmune disorder. The most common form is muscle

weakness that is not accompanied by pain, weakness

is exacerbated by activity and improves when resting.

Exacerbations and remissions can occur, especially in the

first years of the disease. Remission rarely occurs complete

or permanent.

Case Report:

A 35-year-old woman was treated in the

Neurology Department of RSMH due to being unable to

eat and drink due to not being able to swallow slowly.

The diagnosis of myasthenia is made primarily from

clinical presentation, which is based on history taking and

neurological physical examination and continued with

additional work up. In electrophysiological examination,

characteristic of myasthenia which is the rapid reduction

of amplitude in CMAP during serial repetitive stimulation

on peripheral nerve at frequency of 3/ second was found.

Previous diagnosis have been made through ENMG with

Harvey Masland positive without thymoma (normal chest

CT scan). Although a definitive diagnosis is obtained by

examination of antiacetylcholine receptor antibodies, using

repetitive nerve stimulation is quite specific and indicates a

high likelihood that this patient is diagnosed with myasthenia

gravis. Clinically, patients are categorized through the clinical

classification of MGFA as Class IIIb, where the patient mainly

affectstheoropharyngealmuscleswithamoderateweakness.

During treatment the patient was given corticosteroids

and antiacetylcholinesterase. The choice of corticosteroids

and antiacetylcholinesterase as therapy clinically provides

improvement in patients.

Conclusion:

Myasthenia gravis is a fluctuating disease. Clinical

repair and worsening can occur. Exacerbation of myasthenia

is a general term that can be defined as an increase in the

degree of weakness in the bulbar muscles, breathing, or

muscles of the arms and legs. Both conditions of this crisis

show almost the same clinical appearance. The choice of

therapy and dosage must be adjusted to each individual's

condition.

e

:

dr.theresiachristinsp.s@gmail.com